BN Agrochem FY2026: 292% Revenue Spike, Earnings That Got Lost in Translation
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1 — At a Glance
Revenue vaulted ₹873 crore in FY26, a threefold leap from ₹299 crore the year prior. Yet net profit—₹34 crore—feels thin against that headline. The company has been rewriting its script, swallowing overseas acquisitions and capital raises while the promoter stake crumbled from 58.6% to 5.93% in a single quarter.
That collapse isn’t drama. In December 2024, Anubhav Agarwal (then the main promoter at 55.23%) faded into the woodwork. Global Focus Fund, M7 Global, and a constellation of foreign names now own the majority. The balance sheet holds ₹72 crore invested in Epitome Industries and carries ₹50.65 crore in borrowings.
Operating margin limped to 2.5%—barely breathing. A company that had no revenue two years ago is now a ₹2,744 crore market cap entity holding more cash equivalents than operating profit.
Is this a turnaround or a shell game with better optics?
2 — Introduction
BN Agrochem (formerly Arihant Tournesol and then BN Holdings) was incorporated in 1991. For most of its life it was dormant—losing money, reporting no sales, a dusty ticker. In FY24, it stirred. Revenues appeared: ₹7 crore. Losses shrank. By FY26, something snapped awake: the company reported ₹873 crore in sales.
What changed? Overseas ambition. In FY24–FY25, the company:
Incorporated wholly-owned subsidiaries in London (BN Holdings Europe) and Singapore (BN Agrochem Singapore).
Raised external commercial borrowings and issued ₹40 crore in foreign currency convertible bonds.
Acquired a 3.5% stake in Epitome Industries India via ₹72 crore in preference shares.
Allotted 17.9 crore convertible warrants to Global Focus Fund for ₹82.49 crore.
By May 2026, Chintan Ajaykumar Shah became CEO; the founder Anubhav Agarwal stepped back to non-executive chair. Auditors changed. A CFO resigned hours before results. The numbers, in short, are a window into a company mid-metamorphosis.
3 — Business Model: WTF Do They Even Do?
The company deals in oilseeds, edible oils, solvent extraction, refined oils, and oil cakes. On paper, it is an agrochem and food FMCG play. In reality, it is an investment holding company that acquired an operating business.
The operating engine lives in two subsidiaries in Europe and Singapore. The holding company receives trade receivables and other financial assets (₹142 crore as of March 2026), sits on ₹72 crore invested in Epitome, and collects small management fees. This is a classic structure for capital deployment and international tax arbitrage.
The business generates revenue not through branded consumer goods but through commodity oil trading. Two customers—Agusta Global DMCC and KLB International—account for 29% and 58% of revenue respectively. That is a concentration risk that barely needs a chart to be alarming. Lose one, lose the majority of the P&L.
Q4 FY26 (Quarter ended 31 Mar 2026): The quarter itself reported ₹261 crore revenue, ₹4.22 crore operating profit, and ₹2.95 crore net profit. That implied annualised Q4 EPS of ₹0.30 (not multiplied, as Q4 is the full year-close). Full-year annualised EPS: ₹3.52.
Operational Commentary: Revenue growth was brisk; profitability did not keep pace. Operating margin (OPM) was 2.53% for the year—the company kept ₹2.53 of every ₹100 of revenue as operating profit. The prior year’s OPM was 2.3%. Gross spread widened. The tax rate was -74%, a substantial reversal (likely deferred tax benefits or past-year adjustments), which inflated
